Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 6, 2009, Pages 607-620

  Agúndez, José A G ^a   García Martín, Elena ^a   Martínez, Carmen ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

CYP; CYP2C8; CYP2C9; NSAID; Pharmacogenomics; Polymorphisms

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CELECOXIB; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DICLOFENAC; DIPYRONE; DRUG METABOLITE; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; LORNOXICAM; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; ROFECOXIB; SULINDAC; TENOXICAM; VALDECOXIB;

AREA UNDER THE CURVE; CYP2C8 GENE; CYP2C9 GENE; DRUG CLEARANCE; DRUG METABOLISM; GASTROINTESTINAL HEMORRHAGE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; METABOLOMICS; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; REVIEW; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ECONOMICS, PHARMACEUTICAL; GASTROINTESTINAL HEMORRHAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLOMICS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 67649416267     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902970998     Document Type: Review

References (101)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24 (Pubitemid 29183022)
2. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988;84:20-24
3. Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004;11:17-25
4. Walan A, Wahlqvist P. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1999;31(Suppl 1):S79-88 (Pubitemid 29248590)
5. Rahme E, Joseph L, Kong SX, et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52:185-192 (Pubitemid 32863077)
6. Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669-676 •• Excellent overview. (Pubitemid 39150124)
7. Scordo MG, Aklillu E, Yasar U, et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001;52:447-450 (Pubitemid 32939447)
8. Restrepo J, Garcia-Martin E, Martinez C, et al. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab 2009;10:236-246
9. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005;33:1567-1575
10. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [(14)C] celecoxib in healthy male volunteers. Drug Metab Dispos 2000;28:308-314
11. Sandberg M, Yasar U, Stromberg P, et al. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002;54:423-429 (Pubitemid 35334956)
12. Garcia-Martin E, Martinez C, Tabares B, et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004;76:119-127 •• Conclusive evidence for a role of CYP2C8 polymorphism in ibuprofen pharmacokinetics. (Pubitemid 39013402)
13. Chang SY, Li W, Traeger SC, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 2008;36:2513-2522
14. Kuehl GE, Lampe JW, Potter JD, et al. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005;33:1027-1035 (Pubitemid 41002785)
15. Guo Y, Zhang Y, Wang Y, et al. Role of cyp2c9 and its variants (cyp2c9*3 and cyp2c9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005;33:749-753 (Pubitemid 40686627)
16. Zhang Y, Zhong D, Si D, et al. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 2005;59:14-17 (Pubitemid 40044795)
17. Liu YL, Zhang W, Tan ZR, et al. Effect of the CYP2C9*3 allele on lornoxicam metabolism. Clin Chim Acta 2006;364:287-291 (Pubitemid 43124018)
18. Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990;66(Suppl 4):S22-7 (Pubitemid 20364811)
19. Richardson CJ, Blocka KL, Ross SG, et al. Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 1987;32:89-91 (Pubitemid 17039377)
20. Perini JA, Vianna-Jorge R, Brogliato AR, et al. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005;78:362-369 (Pubitemid 41393671)
21. Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992;51:575-581
22. Bort R, Ponsoda X, Carrasco E, et al. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996;24:834-841 (Pubitemid 26274739)
23. Crespi CL, Chang TK, Waxman DJ. Determination of CYP2C9-catalyzed diclofenac 4′-hydroxylation by high-performance liquid chromatography. Methods Mol Biol 2006;320:109-113
24. Bort R, Mace K, Boobis A, et al. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999;58:787-796 (Pubitemid 29329528)
25. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003;4:319-329
26. King C, Tang W, Ngui J, et al. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001;61:49-53 (Pubitemid 32409686)
27. Kumar S, Samuel K, Subramanian R, et al. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 2002;303:969-978 (Pubitemid 35424378)
28. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995;28:100-114
29. Zgheib NK, Frye RF, Tracy TS, et al. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol 2007;63:477-487 (Pubitemid 46426631)
30. Nakajima M, Inoue T, Shimada N, et al. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998;26:261-266 (Pubitemid 28182403)
31. Duggan DE, Hogans AF, Kwan KC, et al. The metabolism of indomethacin in man. J Pharmacol Exp Ther 1972;181:563-575
32. Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998;28:1-13 (Pubitemid 28051312)
33. Ludwig E, Schmid J, Beschke K, et al. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 1999;290:1-8 (Pubitemid 29302296)
34. Dell D, Joly R, Meister W, et al. Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine. J Chromatogr 1984;317:483-492 (Pubitemid 15162589)
35. Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994;26:107-120 (Pubitemid 24064235)
36. Peiro AM, Novalbos J, Zapater P, et al. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol Res 2009;59:62-68
37. Hutt AJ, Caldwell J, Smith RL. The metabolism of aspirin in man: a population study. Xenobiotica 1986;16:239-249 (Pubitemid 16164017)
38. Bigler J, Whitton J, Lampe JW, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001;61:3566-3569 (Pubitemid 32694961)
39. MacDonald CJ, Ciolino HP, Yeh GC. The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 2004;64:429-434
40. Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet 2008;47:703-720
41. Jaggi R, Addison RS, King AR, et al. Conjugation of desmethylnaproxen in the rat-a novel acyl glucuronide-sulfate diconjugate as a major biliary metabolite. Drug Metab Dispos 2002;30:161-166 (Pubitemid 34106534)
42. Bowalgaha K, Elliot DJ, Mackenzie PI, et al. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005;60:423-433 (Pubitemid 41428474)
43. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-349 (Pubitemid 26288624)
44. Halpin RA, Porras AG, Geer LA, et al. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab Dispos 2002;30:684-693 (Pubitemid 34579103)
45. Zhang JY, Zhan J, Cook CS, et al. Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. Drug Metab Dispos 2003;31:652-658 (Pubitemid 36444175)
46. Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001;41:1111-1119 (Pubitemid 32880140)
47. Ibrahim A, Karim A, Feldman J, et al. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 2002;95:667-673, table of contents (Pubitemid 35006862)
48. Agundez JA, Carrillo JA, Martinez C, et al. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine. Ther Drug Monit 1995;17:1-5
49. Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995;25:417-427
50. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995;28:216-234
51. Saito Y, Katori N, Soyama A, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007;17:461-471 (Pubitemid 46905213)
52. Available from: http://www.cypalleles.ki.se/cyp2c8.htm
53. Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40 • Review of human variability for CYP2C8 and CYP2C9 alleles.
54. Hichiya H, Tanaka-Kagawa T, Soyama A, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005;33:630-636 (Pubitemid 40593876)
55. Blaisdell J, Jorge-Nebert LF, Coulter S, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004;14:527-537 (Pubitemid 39106854)
56. Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004;76:210-219 (Pubitemid 39221795)
57. DeLozier TC, Lee SC, Coulter SJ, et al. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther 2005;315:1085-1090 (Pubitemid 41635394)
58. Veenstra DL, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005;77:353-364 (Pubitemid 40719264)
59. Maekawa K, Fukushima-Uesaka H, Tohkin M, et al. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006;16:497-514 (Pubitemid 43922347)
60. Yin T, Maekawa K, Kamide K, et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008;31:1549-1557
61. Garcia-Martin E, Martinez C, Ladero JM, et al. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001;57:47-49 (Pubitemid 32391412)
62. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004;5:211-224 (Pubitemid 38735776)
63. Martinez C, Garcia-Martin E, Ladero JM, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 2001;22:1323-1326 (Pubitemid 32737351)
64. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromolecular Med 2007;9:195-204 (Pubitemid 47065546)
65. Martinez C, Garcia-Martin E, Blanco G, et al. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005;59:62-69 (Pubitemid 40040097)
66. Yasar U, Lundgren S, Eliasson E, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002;299:25-28 (Pubitemid 35366030)
67. Hilli J, Rane A, Lundgren S, et al. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol 2007;21:379-386 (Pubitemid 47084025)
68. Dreisbach AW, Japa S, Sigel A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens 2005;18:1276-1281 (Pubitemid 41400194)
69. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607 (Pubitemid 32953585)
70. Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007;82(2):197-203 (Pubitemid 47075331)
71. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005;77:341-352 (Pubitemid 40719263)
72. Garcia-Martin E, Pizarro RM, Martinez C, et al. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 2006;7:575-585 (Pubitemid 43891414)
73. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16 •• Excellent overview of the impact of CYP2C9 polymorphism in clinical practice. (Pubitemid 40089477)
74. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272-281
75. Blanco G, Martinez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008;18:37-43 • Study on the influence of CYP2C8 and CYP2C9 polymorphisms in the risk of developing gastrointestinal bleeding associated with NSAID. (Pubitemid 351222384)
76. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7:97-104 (Pubitemid 40261834)
77. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719 (Pubitemid 29103806)
78. Agundez JA, Martinez C, Garcia-Martin E, et al. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. Gastroenterology 2007;133:2071-2072 (Pubitemid 350180821)
79. Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004 • Study on the influence of CYP2C9 polymorphisms in the risk of developing gastrointestinal bleeding associated with NSAID. (Pubitemid 38250889)
80. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-263 (Pubitemid 34596790)
81. Tang C, Shou M, Rushmore TH, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001;11:223-235 (Pubitemid 32319872)
82. Kirchheiner J, Tsahuridu M, Jabrane W, et al. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 2004;1:63-84
83. Brenner SS, Herrlinger C, Dilger K, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003;42:283-292 (Pubitemid 36308065)
84. Kirchheiner J, Stormer E, Meisel C, et al. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003;13:473-480 (Pubitemid 37034589)
85. Kusama M, Maeda K, Chiba K, et al. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm Res 2009;26(4):822-835
86. Kirchheiner J, Meineke I, Steinbach N, et al. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003;55:51-61
87. Yasar U, Eliasson E, Forslund-Bergengren C, et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001;57:729-735 (Pubitemid 34031266)
88. Lee CR, Pieper JA, Frye RF, et al. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003;58:791-794
89. Kirchheiner J, Meineke I, Freytag G, et al. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002;72:62-75 (Pubitemid 34833188)
90. Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000;10:95-104
91. Vianna-Jorge R, Perini JA, Rondinelli E, et al. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004;76:18-26 (Pubitemid 38844730)
92. Xu HY, Zhong DF, Zhao LM, et al. Pharmacokinetics of meloxicam in healthy Chinese volunteers. Yao Xue Xue Bao 2001;36:71-73
93. Zarza J, Hermida J, Montes R, et al. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost 2003;90:161-162 (Pubitemid 36873876)
94. Vonkeman HE, van de Laar MA, van der Palen J, et al. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin Ther 2006;28:1670-1676 • Study on the influence of CYP2C9 polymorphisms in the risk of developing gastrointestinal bleeding associated with NSAID. (Pubitemid 44841985)
95. Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to NSAID-related gastroduodenal bleeding: Role of cytochrome P450 (CYP) 2C9 polymorphisms. Gastroenterology 2007;133:465-471 • Study on the influence of CYP2C9 polymorphisms in the risk of developing gastrointestinal bleeding associated with NSAID.
96. van Oijen MG, Laheij RJ. Impact of CYP2C9 genotype on pharmacokinetics: are all NSAIDs the same? Gastroenterology 2007;133:2073-2074
97. Ma J, Yang XY, Qiao L, et al. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. J Dig Dis 2008;9:79-83 • Study on the influence of CYP2C9 polymorphisms in the risk of developing gastrointestinal bleeding associated with NSAID. (Pubitemid 351566628)
98. Ford L, Kampanis P, Berg J. Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann Clin Biochem 2009;46:152-154
99. Palmieri O, Latiano A, Bossa F, et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment Pharmacol Ther 2007;26:737-745 (Pubitemid 47246208)
100. Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci 2006;27:580-586 (Pubitemid 44604301)
101. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-861